NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $38.52 -0.52 (-1.33%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$38.71 +0.19 (+0.49%) As of 10/24/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harrow Stock (NASDAQ:HROW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harrow alerts:Sign Up Key Stats Today's Range$37.69▼$39.7750-Day Range$36.20▼$48.8552-Week Range$20.85▼$54.19Volume527,462 shsAverage Volume896,006 shsMarket Capitalization$1.43 billionP/E RatioN/ADividend YieldN/APrice Target$68.50Consensus RatingModerate Buy Company Overview Harrow Health, Inc. (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders. Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives. Its product portfolio includes preservative-free and compounded prescription eye drop formulations, which are distributed nationwide across all 50 states. The company leverages a targeted commercial infrastructure to support independent ophthalmologists, optometrists and surgical centers, while maintaining a research pipeline aimed at novel delivery technologies and formulations. Originally operating under the name ImprimisRx, the company officially adopted the Harrow Health name in mid-2021 to reflect its broader strategic focus on eye health. Harrow Health is led by Chairman and Chief Executive Officer Robert A. Ward, whose leadership, together with an experienced management team, has driven both commercial expansion and product innovation in the ophthalmology space.AI Generated. May Contain Errors. Read More Harrow Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreHROW MarketRank™: Harrow scored higher than 55% of companies evaluated by MarketBeat, and ranked 582nd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingHarrow has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialHarrow has a consensus price target of $68.50, representing about 77.8% upside from its current price of $38.52.Amount of Analyst CoverageHarrow has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Harrow's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Harrow are expected to grow in the coming year, from ($0.53) to $0.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -154.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -154.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 19.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.05% of the outstanding shares of Harrow have been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Harrow has recently increased by 6.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.05% of the outstanding shares of Harrow have been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Harrow has recently increased by 6.50%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.63 News SentimentHarrow has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Harrow this week, compared to 7 articles on an average week.Search InterestOnly 12 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows5 people have added Harrow to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have not sold or bought any company stock.Percentage Held by Insiders15.16% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HROW Stock News HeadlinesHarrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 20, 2025 | americanbankingnews.comHarrow: Positive And Negative Adjustments After Investor Day Offset Each OtherOctober 15, 2025 | seekingalpha.comArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.October 25 at 2:00 AM | Banyan Hill Publishing (Ad)Harrow Health Announces New Leadership at ImprimisRxOctober 11, 2025 | theglobeandmail.comHarrow, Inc. (HROW): A Bull Case TheoryOctober 8, 2025 | insidermonkey.comCould Harrow’s (HROW) New Pricing Program Redefine Its Patient Access Advantage?October 7, 2025 | finance.yahoo.comHarrow subsidiary ImprimisRx gets new CEOOctober 6, 2025 | msn.comImprimisRx Announces Leadership ChangesOctober 6, 2025 | globenewswire.comSee More Headlines HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $33.55 at the beginning of the year. Since then, HROW shares have increased by 14.8% and is now trading at $38.52. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) issued its quarterly earnings data on Tuesday, July, 18th. The company reported $0.03 earnings per share for the quarter. The company had revenue of $22.12 million for the quarter. Harrow had a negative trailing twelve-month return on equity of 2.18% and a negative net margin of 4.49%. Read the conference call transcript. Who are Harrow's major shareholders? Top institutional investors of Harrow include Rice Hall James & Associates LLC (0.90%), Brookstone Capital Management (0.12%), D.A. Davidson & CO. (0.12%) and Calamos Advisors LLC (0.06%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Martin A Makary and Horn R Lawrence Van. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings7/18/2023Today10/24/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees180Year Founded2012Price Target and Rating Average Price Target for Harrow$68.50 High Price Target$76.00 Low Price Target$63.00 Potential Upside/Downside+77.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.48 million Net Margins-4.49% Pretax Margin-4.71% Return on Equity-2.18% Return on Assets-0.35% Debt Debt-to-Equity Ratio0.78 Current Ratio0.62 Quick Ratio0.58 Sales & Book Value Annual Sales$199.61 million Price / Sales7.14 Cash Flow$0.13 per share Price / Cash Flow285.50 Book Value$1.95 per share Price / Book19.75Miscellaneous Outstanding Shares37,000,000Free Float31,392,000Market Cap$1.43 billion OptionableOptionable Beta0.27 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:HROW) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.